plaque psoriasis
Dermatology · 2005–2026
95decisions
20medicines
37carried consumer input
120individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tildrakizumab Continuing treatment of adults with severe chronic plaque psoriasis who have achieved at least a PASI75 response with tildrakizumab 100 mg. This submission… | Mar 2026 | Noted | input received |
| ustekinumab Treatment of adult patients with severe chronic plaque psoriasis and severe psoriatic arthritis. | Mar 2026 | Recommended | unclear |
| adalimumab Immune-mediated inflammatory diseases (IMIDs) in paediatric patients, including juvenile idiopathic arthritis, Crohn disease, ulcerative colitis, psoriasis,… | Jul 2025 | Deferred | 6 individuals |
| calcipotriol with betamethasone dipropionate Treatment of chronic stable plaque type psoriasis vulgaris in adult patients who have not adequately responded to potent topical corticosteroid monotherapy. | Jul 2025 | Recommended with restriction | none received |
| etanercept General Schedule Authority Required and Section 100 (Highly Specialised Drugs Program) Authority Required listings for severe psoriatic arthritis, ankylosing… | Jul 2025 | Recommended with restriction | none received |
| infliximab Rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing spondylitis, psoriasis, and… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| guselkumab Treatment of adults with severe chronic plaque psoriasis (CPP). | May 2025 | Recommended with restriction | input received |
| infliximab Biosimilar to reference infliximab for multiple indications: rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children/adolescents 6–17… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| infliximab Continuing treatment and balance of supply of infliximab 120 mg subcutaneous injection for ankylosing spondylitis, severe Crohn disease, severe chronic plaque… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| bimekizumab Treatment of severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. | Nov 2025 | Recommended | unclear |
| calcipotriol with betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris, inadequately controlled by potent topical corticosteroid monotherapy. Topical treatment of scalp psoriasis and… | Nov 2025 | Recommended | input received |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2024 | Recommended with restriction | none received |
| adalimumab Complex refractory fistulising Crohn disease, severe Crohn disease, moderate to severe ulcerative colitis, moderate to severe hidradenitis suppurativa, and… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, complex refractory fistulising Crohn… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and… | Nov 2024 | Recommended with restriction | input received Colitis Australia |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2023 | Recommended with restriction | input received |
| calcipotriol with betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris with body surface area involvement of at least 5% and less than 30%, inadequately controlled by potent topical… | Jul 2023 | Recommended with restriction | input received Psoriasis Australia |
| deucravacitinib Severe chronic plaque psoriasis in patients who have not responded to or have a contraindication or demonstrated intolerance to methotrexate. | Mar 2023 | Deferred | input received Creaky Joints Australia |
| bimekizumab Treatment of severe chronic plaque psoriasis in adult patients who have failed to achieve an adequate response with at least two prior therapies. | Mar 2023 | Recommended with restriction | input received Psoriasis Australia |
| tildrakizumab Treatment of severe chronic plaque psoriasis in adults. The submission requests adding grandfathering restrictions to allow PBS access for patients enrolled in… | Mar 2023 | Noted | input received |
| apremilast Severe chronic plaque psoriasis in patients who have failed treatment with, or who are contraindicated or intolerant to, methotrexate. | Nov 2023 | Recommended with restriction | input received Creaky Joints Australia · Global Healthy Living Foundation Australia |
| risankizumab Treatment of severe chronic plaque psoriasis in adult patients who have failed to achieve an adequate response with at least two prior therapies. | Nov 2023 | Recommended with restriction | unclear |
| ustekinumab Treatment of patients with Crohn disease and severe chronic plaque psoriasis requiring a 90 mg dose of ustekinumab, in a 90 mg pre-filled syringe formulation. | Jul 2022 | Recommended | none received |
| apremilast Severe chronic plaque psoriasis in patients who have failed treatment with, or who are contraindicated or intolerant to, methotrexate. | Mar 2022 | Recommended | input received Creaky Joints Australia · Global Healthy Living Foundation Australia |
| bimekizumab Treatment of severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. | Mar 2022 | Recommended with restriction | input received |
| infliximab Treatment of ankylosing spondylitis (AS), severe chronic plaque psoriasis (CPP), severe active psoriatic arthritis (PsA), and complex refractory fistulising… | Mar 2022 | Recommended | unclear |
| risankizumab Extension of existing PBS listings to allow grandfathering of patients enrolled in the risankizumab open label extension trial (M15-997) onto PBS-subsidised… | Mar 2022 | Recommended with restriction | none received |
| adalimumab; upadacitinib Change in restriction levels (Authority Required categories) for adalimumab across multiple indications (rheumatoid arthritis, ankylosing spondylitis,… | Nov 2022 | Noted | 1 individuals |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid arthritis, severe… | Jul 2021 | Recommended with restriction | input received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2021 | Recommended | unclear |
| guselkumab Severe chronic plaque psoriasis. | Mar 2021 | Not recommended | input received |
| ustekinumab Treatment of paediatric patients with severe chronic plaque psoriasis (CPP) defined as a PASI score of greater than 15, who have failed treatment with two of… | Mar 2021 | Recommended with restriction | 1 individuals |
| etanercept Biosimilar to Enbrel for severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile… | Nov 2021 | Recommended with restriction | unclear |
| risankizumab Treatment of moderate to severe plaque psoriasis in adults aged 18 years or older who are candidates for phototherapy or systemic therapy. | Nov 2021 | Recommended | none received |
| secukinumab Treatment of paediatric patients with severe chronic plaque psoriasis in patients under 18 years of age who are candidates for systemic therapy. | Nov 2021 | Recommended with restriction | input received |
| adalimumab Biosimilar to adalimumab for multiple indications including severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe ulcerative… | Jul 2020 | Recommended with restriction | none received |
| secukinumab Chronic plaque psoriasis in patients with baseline PASI ≥12 to ≤15 who have failed to achieve an adequate response to at least two of the following therapies:… | Jul 2020 | Noted | no section in document |
| apremilast Severe chronic plaque psoriasis in patients who have failed treatment with, or are contraindicated or intolerant to, methotrexate. | Jul 2020 | Recommended with restriction | input received |
| guselkumab Treatment of severe chronic plaque psoriasis in adult patients (18 years or older) who are candidates for systemic therapy or phototherapy. | Jul 2020 | Recommended | none received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Mar 2020 | Recommended | input received Colitis Australia |
| etanercept Administrative request to change listing restrictions and authority level for etanercept biosimilar (Brenzys) to support biosimilar uptake in rheumatoid… | Dec 2020 | Not recommended | no section in document |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Treatment of severe active rheumatoid arthritis, moderate to severe ulcerative colitis, and severe refractory Crohn's disease in adult patients via… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| risankizumab Treatment of severe chronic plaque psoriasis in adults who have failed or are contraindicated to conventional therapy. | Jul 2019 | Recommended with restriction | input received |
| certolizumab pegol Treatment of severe chronic plaque psoriasis in adult patients meeting specified PBS criteria who have failed to achieve adequate response, are intolerant or… | Mar 2019 | Recommended with restriction | none received |
| infliximab Increase in maximum quantity from 4 to 5 vials for subsequent continuing treatment of severe Crohn disease, complex refractory fistulising Crohn disease,… | Mar 2019 | Recommended with restriction | 3 individuals |
| certolizumab pegol Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. | Nov 2019 | Recommended with restriction | none received |
| adalimumab Biosimilar of adalimumab for all indications for which Humira is currently PBS listed, including severe active rheumatoid arthritis, severe psoriatic… | Jul 2018 | Recommended with restriction | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| adalimumab Treatment of severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's disease, moderate… | Jul 2018 | Recommended with restriction | none received |
| tildrakizumab Treatment of severe chronic plaque psoriasis in adult patients who have failed conventional therapy. | Jul 2018 | Recommended with restriction | none received |
| apremilast Moderate to severe plaque psoriasis in adults who have failed to achieve an adequate response to methotrexate. | Mar 2018 | Recommended with restriction | 2 individuals Psoriasis Australia |
| calcipotriol with betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris with body surface area involvement of 7–13%, 13–19%, or more than 20%, inadequately controlled by potent topical… | Mar 2018 | Not recommended | none received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile severe chronic plaque… | Mar 2018 | Recommended with restriction | none received |
| guselkumab Treatment of severe chronic plaque psoriasis in adult patients who have failed conventional therapy. | Mar 2018 | Not recommended | 5 individuals |
| etanercept Changes to the listing of etanercept (Brenzys brand) to support biosimilar uptake, including modifications to authority requirements and treatment cycle… | Nov 2018 | Deferred | none received |
| etanercept Severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis. | Aug 2017 | Recommended with restriction | no section in document |
| secukinumab Continuing treatment of severe chronic plaque psoriasis that is refractory to non-biological disease modifying anti-rheumatic drugs (DMARDs). | Jul 2017 | Not recommended | none received |
| apremilast Moderate-to-severe plaque psoriasis in patients who have failed to achieve an adequate response or are contraindicated to treatment with methotrexate. | Mar 2017 | Not recommended | none received |
| apremilast Treatment of moderate to severe plaque psoriasis in adults. Authority required (streamlined) listing for patients who have failed to achieve an adequate… | Nov 2017 | Deferred | 72 individuals |
| infliximab Change to initial and continuing treatment restrictions for infliximab biosimilar, and application of biosimilar uptake measures for multiple indications… | Nov 2017 | Recommended with restriction | none received |
| etanercept Biosimilar etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended with restriction | input received |
| ixekizumab Treatment of severe chronic plaque psoriasis that is refractory to treatment with non-biological DMARDs. | Jul 2016 | Recommended with restriction | input received |
| secukinumab Treatment of chronic plaque psoriasis. This submission sought to amend the PBS restriction to allow an increase in maximum quantity to cover the loading dose… | Mar 2016 | Recommended with restriction | no section in document |
| calcipotriol with betamethasone dipropionate Treatment of chronic stable plaque type psoriasis vulgaris in adults not adequately controlled with vitamin D analogue or potent topical corticosteroid… | Nov 2016 | Recommended with restriction | none received |
| infliximab Biosimilar infliximab for the same indications as Remicade: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis,… | Nov 2016 | Recommended with restriction | none received |
| apremilast Treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy. | Nov 2016 | Not recommended | 27 individuals Psoriasis Australia · Queensland Institute |
| infliximab Biosimilar to Remicade, indicated for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| apremilast Treatment of moderate-to-severe plaque psoriasis in patients who have previously received and failed to achieve an adequate response to one or more systemic… | Mar 2015 | Not recommended | none received |
| secukinumab Severe chronic plaque psoriasis that is refractory to treatment with non-biological disease modifying anti-rheumatic drugs (DMARDs) in patients meeting… | Mar 2015 | Recommended | none received |
| calcipotriol + betamethasone dipropionate Treatment of scalp and body plaque psoriasis in patients not adequately controlled with vitamin D analogue or potent topical corticosteroid monotherapy. | Nov 2015 | Recommended with restriction | none received |
| coal tar prepared Relief of symptoms of psoriasis. | Nov 2014 | Recommended | none received |
| adalimumab Treatment of moderate to severe chronic plaque psoriasis in adult patients with PASI or DLQI greater than 10 and PASI less than or equal to 15, who have failed… | Mar 2013 | Not recommended | unclear |
| etanercept Treatment of severe chronic plaque psoriasis in patients under 18 years of age who have failed at least 2 prior systemic therapies. | Mar 2012 | Recommended with restriction | unclear |
| calcipotriol with betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy. | Jul 2009 | Recommended with restriction | no section in document |
| etanercept Amendment to the treatment regimen for chronic plaque psoriasis to allow etanercept 50 mg/week for 12 weeks initial treatment followed by continuous treatment… | Mar 2009 | Recommended with restriction | no section in document |
| adalimumab Treatment of severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. | Mar 2009 | Recommended with restriction | no section in document |
| ustekinumab Treatment of severe chronic plaque psoriasis in patients who meet PBS criteria for treatment with a biologic. | Nov 2009 | Recommended with restriction | no section in document |
| adalimumab Treatment of severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. | Jul 2008 | Not recommended | no section in document |
| etanercept Severe chronic plaque psoriasis. The submission requested changes to enable patients achieving PASI 50 response at week 12 to continue for 12 additional weeks… | Jul 2008 | Recommended | no section in document |
| adalimumab Treatment of severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. | Jul 2008 | Not recommended | no section in document |
| etanercept Patients with severe chronic plaque psoriasis who achieve a PASI 50 response at week 12 to continue treatment for a further 12 weeks to achieve PASI 75… | Jul 2008 | Recommended | no section in document |
| efalizumab Extension of initial treatment phase from 12 to 24 weeks for chronic plaque psoriasis in patients who achieve a PASI over 50 and less than 75 at 12 weeks. | Nov 2008 | Recommended with restriction | no section in document |
| tazarotene Chronic stable plaque type psoriasis vulgaris. | Jul 2007 | Not recommended | no section in document |
| tazarotene Chronic stable plaque type psoriasis vulgaris. | Jul 2007 | Not recommended | no section in document |
| etanercept A request to change the PBS restriction for patients with severe chronic plaque psoriasis to allow continuous treatment for 'high needs' patients and extend… | Mar 2007 | Not recommended | no section in document |
| infliximab Treatment of severe chronic plaque psoriasis in patients who meet certain criteria, for whom phototherapy or conventional systemic treatments have been… | Jul 2006 | Recommended with restriction | no section in document |
| etanercept Authority required listing for adults with severe chronic plaque psoriasis unresponsive to, contraindicated to, or intolerant to conventional psoriasis… | Mar 2006 | Recommended with restriction | no section in document |
| Coal tar prepared Treatment of chronic plaque psoriasis of the skin and scalp. | Jul 2005 | Recommended | no section in document |
| efalizumab Adults with severe chronic plaque psoriasis who have failed to achieve an adequate response to, or are contraindicated to, at least two systemic therapies. | Jul 2005 | Not recommended | no section in document |
| etanercept Severe chronic plaque psoriasis in adults unresponsive to, contraindicated to, or intolerant to conventional psoriasis therapies. | Jul 2005 | Not recommended | no section in document |
| alefacept Treatment of severe chronic plaque psoriasis in adult patients with PASI score ≥15 who are refractory, intolerant or contraindicated to currently available… | Nov 2005 | Not recommended | no section in document |
| efalizumab Treatment of severe chronic plaque psoriasis in adult patients who are refractory to multiple systemic therapies (methotrexate, cyclosporin, and phototherapy)… | Nov 2005 | Recommended with restriction | no section in document |
| alefacept Treatment of severe chronic plaque psoriasis in adult patients who have a Psoriasis Area and Severity Index (PASI) score ≥15 and are refractory, intolerant or… | Nov 2005 | Not recommended | no section in document |
| efalizumab Treatment of severe chronic plaque psoriasis in adult patients who are refractory to systemic therapies (methotrexate, cyclosporin, phototherapy) and have a… | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · Psoriasis Australia · Creaky Joints Australia · Global Healthy Living Foundation Australia · Australasian Society of Clinical Immunology and Allergy · Queensland Institute
What the PBS pays
$2,973M in government benefit over 2024–25, across 6,037,596 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| biologics (etanercept, infliximab, adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, tildrakizumab) | $1,241.7M |
| ustekinumab | $538.3M |
| adalimumab | $241.9M |
| guselkumab | $167.6M |
| secukinumab | $120.2M |
| risankizumab | $108.9M |
| infliximab | $83.8M |
| etanercept | $79.8M |
| ixekizumab | $70M |
| certolizumab pegol | $57.5M |
| bimekizumab | $54.8M |
| calcipotriol + betamethasone dipropionate | $41.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 17 technologies for this condition, recommending 17 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| deucravacitinibDeucravacitinib for treating moderate to severe plaque psoriasis | TA907 | recommended restricted | 2023-06 |
| secukinumabSecukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | recommended restricted | 2021-10 |
| bimekizumabBimekizumab for treating moderate to severe plaque psoriasis | TA723 | recommended restricted | 2021-09 |
| risankizumabRisankizumab for treating moderate to severe plaque psoriasis | TA596 | recommended restricted | 2019-08 |
| certolizumab pegolCertolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | recommended restricted | 2019-04 |
| tildrakizumabTildrakizumab for treating moderate to severe plaque psoriasis | TA575 | recommended restricted | 2019-04 |
| guselkumabGuselkumab for treating moderate to severe plaque psoriasis | TA521 | recommended restricted | 2018-06 |
| brodalumabBrodalumab for treating moderate to severe plaque psoriasis | TA511 | recommended restricted | 2018-03 |
| dimethyl fumarateDimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | recommended restricted | 2017-09 |
| adalimumab etanercept and ustekinumabAdalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | recommended restricted | 2017-07 |
| ixekizumabIxekizumab for treating moderate to severe plaque psoriasis | TA442 | recommended restricted | 2017-04 |
| apremilastApremilast for treating moderate to severe plaque psoriasis | TA419 | recommended restricted | 2016-11 |
Showing the 12 most recent of 17.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 37 of 72 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.